AstraZeneca PLC (NYSE: AZN) Q2 2020 earnings call dated July 30, 2020 Corporate Participants: Pascal Soriot -- Executive Director and Chief Executive Officer Dave
AstraZeneca PLC (AZN) Q2 2020 Earnings Call Transcript
Categories
biopharma
Nektar Therapeutics (NASDAQ: NKTR) Q1 2020 Earnings Call Transcript
Nektar Therapeutics (NKTR) Q1 2020 earnings call dated May 07, 2020 Corporate Participants: Jennifer Ruddock -- Senior Vice President, Strategy and Corporate Affairs Howard
Affimed N.V. (NASDAQ: AFMD) Q1 2020 Earnings Call Transcript
Affimed N.V. (AFMD) Q1 2020 earnings call dated Jun. 23, 2020 Corporate Participants: Alexander Fudukidis -- Head of Investor Relations Adi Hoess -- Chief Executive Officer
Veru Inc. (NASDAQ: VERU) Q2 2020 Earnings Call Transcript
Veru Inc. (VERU) Q2 2020 earnings call dated May 13, 2020 Corporate Participants: Sam Fisch -- Director of Investor Relations Mitchell Steiner -- Chairman, President and
Veru (VERU) posts narrower-than-expected loss in Q2
Veru Inc. (NASDAQ: VERU) reported its financial results for the quarter ended March 31, 2020, on Wednesday before the market opens. The
Bristol-Myers Squibb Co (NYSE: BMY) Q1 2020 Earnings Call Transcript
Bristol-Myers Squibb Co (BMY) Q1 2020 earnings call dated May. 07, 2020 Corporate Participants: Timothy Power -- Vice President, Investor Relations Giovanni Caforio -- Chairman of
Novartis International AG (NYSE: NVS) Q1 2020 Earnings Call Transcript
Novartis International AG (NVS) Q1 2020 earnings call dated Apr. 28, 2020 Corporate Participants: Samir Shah -- Global Head of Investor Relations Vasant Narasimhan -- Chief
Celgene (CELG) Q3 profit jumps 56% beats estimates
Celgene Corporation (NASDAQ: CELG) reported a 56% jump in earnings for the third quarter of 2019 helped by higher revenue as well
Sarepta Therapeutics beats Q2 bottom and topline estimates
Sarepta Therapeutics (NASDAQ: SRPT) reported a 29% rise in second quarter revenue, aided by the continuing increase in demand for EXONDYS 51
MediWound stock plunges to a record low on gloomy future
MediWound Ltd. (NASDAQ: MDWD) stock plunged to a record low of $3.52 on Tuesday. The future of the biopharmaceutical company looks gloomy
CymaBay Therapeutics stock drops to 2-year low after bitter NASH study data
CymaBay Therapeutics (NASDAQ: CBAY) stock fell to a two-year low of $4.82 on Tuesday after disappointing nonalcoholic steatohepatitis (NASH) trial data. The
CorMedix reports upbeat Q1 results; provides business update
Biopharmaceutical company CorMedix (CRMD) reported its first quarter 2019 results after the bell today. CorMedix recorded a net loss of $5.2 million
MannKind posts narrower-than-expected Q1 loss
MannKind Corporation (NASDAQ: MNKD) reported a narrower loss in the first quarter of 2019 helped by higher total revenues. The bottom line
Earnings Preview: Aurinia’s Q4 results pivot on AURORA trial updates
Shares of Aurinia Pharmaceuticals (NASDAQ: AUPH/TSX: AUP) rose 13% on February 25 when the US patent office extended the patent protection for
Q4 Earnings Preview: All eyes on Neutrolin trial updates from CorMedix
Biopharma firm CorMedix (NYSE American: CRMD) has seen its shares skyrocket more than 500% in the last 12 months as investors are
GW Pharma stock rises after reporting earnings results for the quarter ended Dec. 31, 2018
As GW Pharmaceuticals (GWPH) moved its fiscal year beginning to January 1, 2019, the company reported financial results for the quarter ended 31
Immunomedics tanks after CEO Michael Pehl’s exit and ‘transition period’ results
Immunomedics (IMMU) plunged about 10% in the extended trading hours after the company announced about CEO Michael Pehl's exit from the role
GE’s stock soars around 15% on news of Biopharma business sale to Danaher
General Electric’s (GE) stock jumped around 15% in premarket hours on Monday after the company announced the sale of its BioPharma business
AbbVie slips to loss in Q4, misses estimates
AbbVie Inc. (ABBV) slipped to a loss in the fourth quarter from a profit last year, due to the inclusion of the
Axsome Therapeutics almost doubles on positive outcome from Alzheimer’s disease trial
Clinical stage biopharmaceutical company Axsome Therapeutics (AXSM) announces positive outcome for ADVANCE-1 trial associated with the treatment of Alzheimer's disease. Shares of Axsome Therapeutics
Flexion Therapeutics plunges after reporting preliminary Q4 financial results
Flexion Therapeutics (Nasdaq: FLXN) reported its preliminary fourth quarter earnings results after the bell today. The biopharmaceutical company's Q4 revenue is expected to be